Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Trial to Evaluate the Efficacy and Safety of the Oral sGC stImulator Vericiguat to Improve Physical Functioning in Activities of Daily Living in Patients With Heart Failure and Preserved Ejection Fraction (VITALITY-HFpEF)

NCT03547583 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03547583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03547583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Trial to Evaluate the Efficacy and Safety of the Oral sGC stImulator Vericiguat to Improve Physical Functioning in Activities of Daily Living in Patients With Heart Failure and Preserved Ejection Fraction (VITALITY-HFpEF)
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2018
Completion date
November 4, 2019
Enrollment
789 (actual)
Sites
177

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure with preserved ejection fraction